Redx Pharma Lung Disease Treatment Receives US FDA Orphan Drug Designation
21 Agosto 2023 - 9:17AM
Dow Jones News
By Michael Susin
Redx Pharma's lung disease treatment RCX007 has received orphan
drug designation from the U.S. Food and Drug Administration for the
potential treatment of idiopathic pulmonary fibrosis, the company
said Monday.
The clinical-stage biotechnology company said the designation
provides various development and commercial incentives, including
market exclusivity, in order to address unmet demand.
The treatment is currently in a Phase 2 clinical study for IPF,
with topline data expected to be released in the first quarter of
2024.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 21, 2023 03:02 ET (07:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Redx Pharma (LSE:REDX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Redx Pharma (LSE:REDX)
Storico
Da Mag 2023 a Mag 2024